Press Release

New Therapeutic Target in the Fight Against ALS

Scientists uncover a new protein in a pathway for neurotoxicity and cell death A new study published in Nature takes us one step forward in understanding the key mechanisms behind neurodegenerative diseases. With the urgent need for human cellular models to study such pathologies, scientists have developed a new 2D cell culture model with features mirroring those of human brains, with the support from MaxWell Biosystems’ high-density Microelectrode arrays (HD-MEAs). Delving deeper into the effects of the abnormal accumulation of TAR DNA-binding protein…

Read More

HyVIS project

MaxWell Biosystems Becomes a Key Partner in a €3M EU-Financed Project “HyVIS”: Next Generation Prosthesis for Visual Restoration Hybrid Synapse for Vision (HyVIS) is a project funded by European Union Horizon 2020 FET-OPEN program 1, which aims to combine several technologies to achieve the groundbreaking restoration of synaptic light-mediated input in retinas with impaired photoreceptors, leading to treatments for diseases such as in retinitis pigmentosa and age-related macular degeneration (AMD). The key focus of HyVIS project is the development of an artificial light-sensitive prosthesis,…

Read More

MaxWell Biosystems Completes CHF 4 million Series A Financing Round

Zurich, Switzerland, 16 December 2020 – MaxWell Biosystems AG, a spin-off from ETH Zürich founded in 2016 announced today the closing of a CHF 4 million Series A financing round to further industrialize and scale-up the production of their consumables, so called multiwell high-density microelectrode array (HD-MEA) plates. Such scale-up will enable the customers of MaxWell Biosystems in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to accelerate the development of drugs targeting…

Read More

Neuroservice and MaxWell Biosystems announce strategic partnership

Neuroservice and MaxWell Biosystems announce strategic partnership to develop HD-MEA assays for human iPSC-derived neurons and other cell cultures Aix-en-Provence, FRANCE and Zurich, SWITZERLAND – October 28, 2020. Today, Neuroservice and MaxWell Biosystems are thrilled to announce a strategic partnership aiming to provide the pharmaceutical industry with a new state-of-the-art CNS in vitro cell electrophysiological solution based on high-density microelectrode array recording of human iPSC-derived neurons and other neuron cultures. The partnership will combine the MaxTwo high-density microelectrode array (HD-MEA)…

Read More

MaxWell Biosystems appoints Dr. Marcel Suter as new VP Operations

Zurich, Switzerland – September 30, 2020 MaxWell Biosystems AG is pleased to announce the appointment of Dr. Marcel Suter as the new Vice President of Operations, effective September 1, 2020. In this new position, Dr. Suter will oversee the company’s operational units, including, supply chain, production, logistics, procurement, and quality control. He will report directly to Dr. Urs Frey, CEO. With more than eight years of experience as project manager and as VP Operations at Optotune, an optics company, Dr.…

Read More
Contact Us






Albisriederstrasse 253
8047 Zurich, Switzerland
+41 44 244 24 24
Schedule a call
info@mxwbio.com
Subscribe to our Newsletter